Oral levosimendan improves cardiac function and hemodynamics in patients with severe congestive heart failure

This publication has 14 references indexed in Scilit:

• Influence of the Novel Inotropic Agent Levosimendan on Isometric Tension and Calcium Cycling in Failing Human Myocardium
  Circulation, 1998
• Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting
  Published by Oxford University Press (OUP) ,1998
• Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers*
  Clinical Pharmacology & Therapeutics, 1997
• The treatment of heart failure: The Task Force of the Working Group on Heart Failure of the European Society of Cardiology
  European Heart Journal, 1997
• Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan
  Journal of Molecular and Cellular Cardiology, 1995
• Effects of Levosimendan, a Cardiotonic Agent Targeted to Troponin C, on Cardiac Function and on Phosphorylation and Ca ²⁺ Sensitivity of Cardiac Myofibrils and Sarcoplasmic Reticulum in Guinea Pig Heart
  Circulation Research, 1995
• Hemodynamic and neurohumoral effects of levosimedan, a new calcium sensitizer, at rest and during exercise in healthy men
  The American Journal of Cardiology, 1995
• Pharmacokinetics of Levosimendan in Healthy Volunteers and Patients with Congestive Heart Failure
  Journal of Cardiovascular Pharmacology, 1995
• Dose-Range Study of a New Calcium Sensitizer, Levosimendan, in Patients with Left Ventricular Dysfunction
  Journal of Cardiovascular Pharmacology, 1995
• Plasma 3, 4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4- hydroxyphenylglycol (MHPG) are insensitive indicators of α2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers
  Life Sciences, 1991